ERBB2 and breast carcinoma: However, both tests are semi-quantitative and require sophisticated laboratory techniques and instrumentation, therefore, it is desirable to develop simpler, sensitive, rapid, and scaleable genetic detection methods to check the HER2 status of breast cancer patients [8], [9].